Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NewGenIvf Group’s growth rises and falls with the number of families its clinics help each quarter. That makes every SEC document—from average IVF cycle pricing in Thailand to MicroSort-driven success rates—essential reading. Yet locating patient-volume metrics hidden inside lengthy healthcare jargon can be daunting.
Stock Titan’s AI removes the guesswork. It scans every NewGenIvf Group quarterly earnings report 10-Q filing and delivers plain-English insights on segment revenue, clinic utilisation and regulatory risks. After each release, the dashboard adds a concise NewGenIvf Group earnings report filing analysis so you can spot margin shifts before the market reacts. Need immediate visibility into executive moves? Our system streams NewGenIvf Group Form 4 insider transactions real-time, alerting you the moment a director buys or sells.
Here’s what you’ll find in one place:
- NewGenIvf Group annual report 10-K simplified for long-term trend tracking
- NewGenIvf Group proxy statement executive compensation details, including option grants
- NewGenIvf Group 8-K material events explained alongside timeline visualisations
- NewGenIvf Group insider trading Form 4 transactions archived and searchable
Whether you’re comparing quarter-over-quarter embryo transfer volumes or monitoring capital raises for new clinics, you’ll find NewGenIvf Group SEC filings explained simply. Understanding NewGenIvf Group SEC documents with AI now takes minutes, not hours—so you can focus on making informed decisions.
NewGenIvf Group Limited is implementing a one-for-five reverse stock split of its issued and unissued Class A Ordinary Shares. The reverse split will be effective at 12:01 a.m. (ET) on December 1, 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq the same day under the existing ticker NIVF.
The reverse split will reduce the number of outstanding Class A Ordinary Shares from 6,585,672 to approximately 1,317,135, so every five existing shares will be combined into one new share. No fractional shares will be issued; any shareholder who would otherwise receive a fraction will receive one whole post-split share instead. All outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amount by five, rounded to the nearest whole share.
NewGenIvf Group Limited approved a 1‑for‑5 reverse stock split to support compliance with Nasdaq’s minimum
The action will reduce outstanding Class A Ordinary Shares from approximately 4,844,490 to approximately 968,898. Every five pre‑split Class A shares will automatically combine into one post‑split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole post‑split share at the participant level. Outstanding options, warrants and other convertibles will be adjusted by dividing the underlying share counts by five. No shareholder vote is required under BVI law, par value remains nil, and the authorized share amount is unlimited and unaffected.
NewGenIvf Group Limited announced a share repurchase program of up to US$2 million, as indicated in Exhibit 99.1 to a Form 6-K filing. Share repurchases can support shareholder value by decreasing the number of shares available in the market over time. The filing lists the program amount but does not include additional terms in this excerpt.
NewGenIvf Group Limited (NIVF) furnished a Form 6-K reporting that NewGenDigital has been appointed as SAXA Inc.’s agent for the tokenization of US$100 million of gold-backed assets. The filing lists this appointment under an accompanying company announcement.
The report was signed by the company’s Chairman, Wing Fung Alfred Siu, on November 5, 2025. No additional financial results or operating metrics are included in this submission beyond the appointment and the stated asset value.
NewGenIvf Group Limited filed a prospectus to register the resale of up to 50,000,000 Class A Ordinary Shares by selling securityholders. This includes 20,000,000 shares issuable to White Lion under a Common Stock Purchase Agreement and 30,000,000 shares issuable to JAK Opportunities VI LLC upon conversion of notes and exercise of warrants.
The company is not selling securities in this offering and will not receive proceeds from resales. Separately, it may receive up to $500,000,000 from sales of newly issued shares to White Lion under the purchase agreement, subject to its terms. The agreement includes a 4.99% beneficial ownership cap (at White Lion’s discretion, up to 9.99%).
As context, shares outstanding were 2,952,702 as of October 31, 2025. The company effected a 1-for-20 reverse stock split on February 11, 2025 and subsequently regained compliance with Nasdaq’s minimum bid price rule; its shares trade on Nasdaq Capital Market under NIVF.
FAQ
What is the current stock price of NewGenIvf Group (NIVF)?
What is the market cap of NewGenIvf Group (NIVF)?
